Rolvedon Drives Company Q4 Revenue to $12.8M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy ASRT?
Reports Q4 revenue $12.8M, consensus $6.2M. Mark Reisenauer, Chief Executive Officer, stated: "Our core asset, Rolvedon, continues to represent a meaningful revenue opportunity, as reflected in both our 2025 results and 2026 outlook, and our strong commercial infrastructure and market access capabilities provide a platform to expand and build an oncology portfolio in a disciplined way. Since taking over as CEO, I've taken a close look at our business to understand where we have a real advantage and where we need to stay disciplined. That has reinforced our focus on finding products that leverage our existing capabilities rather than pursuing on-market specialty product acquisitions, which we do not view as a sustainable path for long-term growth. Our priorities are clear: leverage our core strengths, allocate capital thoughtfully, and build a differentiated oncology franchise that drives durable shareholder value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.060
Low
35.00
Averages
40.00
High
45.00
Current: 19.060
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Assertio Holdings Q4 2025 Earnings Call Insights
- Strategic Shift: Assertio's CEO Mark L. Reisenauer emphasized a pivot towards prioritizing Rolvedon growth, moving away from previous acquisition strategies, with new labeled sales expected to commence in Q2 2026, thereby reinforcing its market share position.
- Financial Performance: Total product sales for Q4 2025 were $12.8 million, a significant drop from $29.6 million year-over-year, primarily due to timing issues with Rolvedon channel inventory; however, gross margin improved to 75%, reflecting effective cost control measures.
- Future Outlook: The company projects fiscal 2026 revenue guidance between $110 million and $125 million, with adjusted EBITDA expected to range from $28 million to $40 million, indicating optimism regarding Rolvedon sales growth and market share expansion.
- Risks and Challenges: Management highlighted risks from increased competition and natural declines in legacy assets, particularly anticipating a year-over-year decline for Indocin due to new generic entrants, stressing the need to maximize Rolvedon sales to offset these headwinds.
See More
Assertio (ASRT) Q4 2025 Earnings Call Transcript
See More
Assertio Holdings Releases 2026 Operating Guidance
- Earnings Beat: Assertio Holdings reported a Q4 Non-GAAP EPS of -$1.06, surpassing expectations by $0.74, indicating resilience despite a 57.9% year-over-year revenue decline to $13.54 million, which exceeded forecasts by $7.32 million, showcasing effective cost management.
- Future Guidance: The company provided its initial 2026 operating guidance, projecting GAAP net product sales between $110 million and $125 million, and adjusted EBITDA (Non-GAAP) of $28 million to $40 million, reflecting management's confidence in future growth and offering clear financial targets for investors.
- Compliance Recovery: Assertio regained Nasdaq compliance following a recovery in its bid price, which not only boosts investor confidence but also paves the way for future capital market activities, demonstrating stability in the market.
- Stock Split Impact: The company announced a 1-for-15 reverse stock split aimed at increasing the share price to attract more institutional investors while improving liquidity, which could positively impact long-term shareholder returns.
See More
Assertio Holdings to Announce Q4 Earnings on March 16
- Earnings Announcement: Assertio Holdings is set to release its Q4 earnings on March 16 after market close, with a consensus EPS estimate of -$1.80, reflecting a staggering 5900% year-over-year decline, indicating severe profitability challenges ahead.
- Revenue Decline: The consensus revenue estimate stands at $6.2 million, representing an 80.7% year-over-year drop, which highlights significant challenges in market competition and product sales, potentially impacting the company's liquidity moving forward.
- Historical Performance: Over the past two years, Assertio has beaten EPS estimates 75% of the time and revenue estimates 75% of the time; however, the current financial outlook suggests increasing pressure that may undermine investor confidence.
- Compliance Recovery: Assertio recently regained Nasdaq compliance following a recovery in its bid price, although the company executed a 1-for-15 reverse stock split, market sentiment regarding its future performance remains skeptical.
See More
Assertio Holdings to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Assertio Holdings will announce its fourth quarter and full year 2025 financial results on March 16, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings release, management will host a live webcast of the earnings call at 4:30 p.m. Eastern Time, providing investors with a direct opportunity to engage with management and enhance investor confidence.
- Access Information: Investors can visit Assertio's investor relations website to access the live webcast, conference call details, and other materials, ensuring they connect at least 10 minutes prior to the call for any necessary software downloads.
- Telephone Access Option: For those wishing to join by phone only, investors can dial +1 (646) 307-1963 and use call ID 3278948, ensuring flexibility in participation methods to meet investor needs.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Assertio Holdings Q4 2025 Earnings Call Insights
- Strategic Shift: Assertio's CEO Mark L. Reisenauer emphasized a pivot towards prioritizing Rolvedon growth, moving away from previous acquisition strategies, with new labeled sales expected to commence in Q2 2026, thereby reinforcing its market share position.
- Financial Performance: Total product sales for Q4 2025 were $12.8 million, a significant drop from $29.6 million year-over-year, primarily due to timing issues with Rolvedon channel inventory; however, gross margin improved to 75%, reflecting effective cost control measures.
- Future Outlook: The company projects fiscal 2026 revenue guidance between $110 million and $125 million, with adjusted EBITDA expected to range from $28 million to $40 million, indicating optimism regarding Rolvedon sales growth and market share expansion.
- Risks and Challenges: Management highlighted risks from increased competition and natural declines in legacy assets, particularly anticipating a year-over-year decline for Indocin due to new generic entrants, stressing the need to maximize Rolvedon sales to offset these headwinds.
See More
Assertio (ASRT) Q4 2025 Earnings Call Transcript
See More
Assertio Holdings Releases 2026 Operating Guidance
- Earnings Beat: Assertio Holdings reported a Q4 Non-GAAP EPS of -$1.06, surpassing expectations by $0.74, indicating resilience despite a 57.9% year-over-year revenue decline to $13.54 million, which exceeded forecasts by $7.32 million, showcasing effective cost management.
- Future Guidance: The company provided its initial 2026 operating guidance, projecting GAAP net product sales between $110 million and $125 million, and adjusted EBITDA (Non-GAAP) of $28 million to $40 million, reflecting management's confidence in future growth and offering clear financial targets for investors.
- Compliance Recovery: Assertio regained Nasdaq compliance following a recovery in its bid price, which not only boosts investor confidence but also paves the way for future capital market activities, demonstrating stability in the market.
- Stock Split Impact: The company announced a 1-for-15 reverse stock split aimed at increasing the share price to attract more institutional investors while improving liquidity, which could positively impact long-term shareholder returns.
See More
Assertio Holdings to Announce Q4 Earnings on March 16
- Earnings Announcement: Assertio Holdings is set to release its Q4 earnings on March 16 after market close, with a consensus EPS estimate of -$1.80, reflecting a staggering 5900% year-over-year decline, indicating severe profitability challenges ahead.
- Revenue Decline: The consensus revenue estimate stands at $6.2 million, representing an 80.7% year-over-year drop, which highlights significant challenges in market competition and product sales, potentially impacting the company's liquidity moving forward.
- Historical Performance: Over the past two years, Assertio has beaten EPS estimates 75% of the time and revenue estimates 75% of the time; however, the current financial outlook suggests increasing pressure that may undermine investor confidence.
- Compliance Recovery: Assertio recently regained Nasdaq compliance following a recovery in its bid price, although the company executed a 1-for-15 reverse stock split, market sentiment regarding its future performance remains skeptical.
See More
Assertio Holdings to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Assertio Holdings will announce its fourth quarter and full year 2025 financial results on March 16, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings release, management will host a live webcast of the earnings call at 4:30 p.m. Eastern Time, providing investors with a direct opportunity to engage with management and enhance investor confidence.
- Access Information: Investors can visit Assertio's investor relations website to access the live webcast, conference call details, and other materials, ensuring they connect at least 10 minutes prior to the call for any necessary software downloads.
- Telephone Access Option: For those wishing to join by phone only, investors can dial +1 (646) 307-1963 and use call ID 3278948, ensuring flexibility in participation methods to meet investor needs.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
